Kimijima, Izo <br/><br/>
[CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group].  [electronic resource] 

 -  Gan to kagaku ryoho. Cancer & chemotherapy  May 2002 
 - 741-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0385-0684 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents--administration & dosage<br/>Aromatase Inhibitors<br/>Breast Neoplasms--drug therapy<br/>Drug Administration Schedule<br/>Enzyme Inhibitors--administration & dosage<br/>Estrogens--blood<br/>Female<br/>Humans<br/>Letrozole<br/>Middle Aged<br/>Nitriles--administration & dosage<br/>Postmenopause<br/>Survival Rate<br/>Triazoles--administration & dosage